Skip to main content
TipRanks
Go Ultimate75% OFF

Tango Therapeutics (TNGX) Drug Pipeline

546 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Rmc-6236, Tng462, Rmc-9805Pancreatic Cancer Metastatic, Lung Cancer, Nsclc, Pdac, Pdac - Pancreatic Ductal Adenocarcinoma, Ras Mutation, Mtap Deletion, Thoracic Cancerphase1AndPhase2RecruitingStudy to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsMar 28, 2025―
Tng462, S095035Mtap-Deleted Solid Tumorsphase1AndPhase2RecruitingS095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAPDec 18, 2023―
Pembrolizumab, Tng260Non Small Cell Lung Cancer, Lung Cancer, Solid Tumors, Adult, Lung Adenocarcinomaphase1AndPhase2RecruitingStudy of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid TumorsApr 18, 2023―
Pembrolizumab, Tng462Locally Advanced Solid Tumorphase1AndPhase2RecruitingSafety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsJan 30, 2023―
Tng908Locally Advanced Solid Tumorphase1AndPhase2Active Not RecruitingSafety and Tolerability of TNG908 in Patients With MTAP-deleted Solid TumorsFeb 18, 2022―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Tango Therapeutics, Inc. (TNGX) have in its pipeline
Tango Therapeutics TNGX is currently developing the following drugs: Rmc-6236, Tng462, Rmc-9805, Tng462, S095035, Pembrolizumab, Tng260, Pembrolizumab, Tng462, Tng908. These drug candidates are in various stages of clinical development as the company works toward FDA approval.